Other
Polyp
1
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Polyp is an early-stage landscape with 1 program across 1 company. The most active players are Fresenius Kabi Oncology Ltd.. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
18
clinical trials
Completed11 · 61%
Unknown status3 · 17%
Recruiting2 · 11%
Terminated1 · 6%
Withdrawn1 · 6%
Clinical Trials
Trial Activity
18 trials
Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients
Completed·—·Phase 4·NCT03903133·50 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)